open access
메뉴
open access
메뉴
ISSN : 0376-4672
Bisphosphonate 약물은 파골세포의 기능을 억제함으로써, 다발성 골수종, 파젯씨 병, 악성종양의 전이로 인한 악성골 질환, 그리고 심한 골다공증의 치료에 사용되어 왔다. 최근 Bisphosphonate 약물의 제형이 다양화 되면서, 심한 골다공증의 치료 외에도 예방적인 목적으로 그 사용이 점점 증가하고 있다. 호르몬 치료등 기존의 골다공증 치료 약물보다 비교적 안전하고 효과적인 약물로 알려져 있었지만, 사용이 증가하면서 예상하지 못한 합병증이 보고되었는데, 그 중 대표적인 것이 치과와 관련된 주제, 즉 악골괴사 (Bisphosphonate related osteonecrosis of the jaw, 이후 BRONJ)이다.
Bisphosphonate inhibits the function of osteoclast, so they are widely used for multiple myeloma, Paget’s disease, metastatic malignant bone disease, and severe osteoporosis. This drug is very effective for preventing severe complication of osteoporosis,some unpredictable complication occurred such as esophageal malignancy, atypical fracture of femur, and osteonecrosis of the jaw. Bisphosphonate related osteonecrosis of the jaw (BRONJ) is closely related with invasive, open bone surgery like tooth extraction. BRONJ associated with dental implant is rare, however, as the use of bisphosphonate increase, BRONJ cases with dental implant are increasing. In this article, we will describe the considerations during dental implant treatment for patient under bisphosphonate therapy.
1. Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw-a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg 2011;49(4):251-257.
2. Yoneda T, Hagino H, Sugimoto T, et al. Bisphosphonaterelated osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28(4):365-383.
3. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.
4. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009;35(3):119-130.
5. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136(8):1117-1124.
6. Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65(12):2397-2410.
7. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86(11):1013-1021.
8. Markiewicz MR, Margarone JE, 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136(12):1669-1674.
9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-1117.
10. Schwartz JE. Ask us: Some drugs affect tooth movement. Am J Orthod Dentofacial Orthop 2005;127(6):644.
11. Zahrowski JJ. Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis. Am J Orthod Dentofacial Orthop 2009;135(3):361-374.
12. Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 2007;131(3):321-326.
13. Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007;131(3):311-320.
14. Taguchi A. Triage screening for osteoporosis in dental clinics using panoramic radiographs. Oral Dis 2010;16(4):316-327.
15. Taguchi A, Asano A, Ohtsuka M, et al. Observer performance in diagnosing osteoporosis by dental panoramic radiographs: results from the osteoporosis screening project in dentistry (OSPD). Bone 2008;43(1):209-213.
16. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 2008;66(5):1022-1024.
17. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66(2):223-230.
18. Javed F, Almas K. Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol 2010;81(4):479-484.
19. Shirota T, Nakamura A, Matsui Y, et al. Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case. Clin Oral Implants Res 2009;20(12):1402-1408.
20. Bedogni A, Bettini G, Totola A, et al. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg 2010;68(7):1662-1666.
21. Goss A, Bartold M, Sambrook P, Hawker P. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg 2010;68(2):337-343.
22. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68(4):790-796.
23. Martin DC, O'Ryan FS, Indresano AT, et al. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg 2010;68(3):508-514.